Inflammation: Evidence-Based Supplement Guide

Nine of the 72 people in Avelor with a saved stack hold something taken for inflammation. It is the vaguest category in the product, and the vagueness is the first problem to deal with. "Inflammation" covers a blood marker that predicts cardiovascular risk, a diagnosed autoimmune disease, and the ordinary soreness after training. Those are three different things, they respond to different interventions, and a product that claims to help with inflammation is usually not saying which one it means. Start with what the marker is and is not. High-sensitivity C-reactive protein is a **risk predictor measured in populations**, not a symptom you feel. A national cohort study found that people high on both it and an insulin-resistance marker had the highest cardiovascular risk (PMID 38715129). Each marker explained only a small share of the other's association with disease. A study in primary and secondary prevention populations examined it alongside lipoprotein(a) (PMID 38353970). Moving a number that predicts risk is not the same as reducing risk, and no supplement below has been shown to do the second by doing the first. None of which means the test was not worth having. It matters. It just does not mean what the supplement aisle implies it means. Curcumin is the compound this category is built on, and the honest reading is more complicated than the label. A GRADE-assessed systematic review and dose-response meta-analysis pooled 66 randomised trials of curcumin and turmeric in adults (PMID 36804260). It found significant reductions in three inflammatory markers, CRP, TNF-alpha and IL-6, and no significant change in a fourth, IL-1beta. Grading the certainty is what makes it the right entry point rather than any single trial. A separate systematic review and meta-analysis in rheumatoid arthritis, a diagnosed condition rather than a marker, reported improvements in sedimentation rate, disease activity score, and swollen and tender joint counts (PMID 37325651). The complication is absorption: curcumin is poorly absorbed, which has been known and described for a long time (PMID 17999464). Piperine from black pepper was shown to raise its bioavailability (PMID 9619120), and a review covers the co-supplementation literature that followed (PMID 36720711). So two products both labelled curcumin can deliver very different amounts, which makes trial results hard to read across to whatever is on your shelf. The rest of the category divides into things with narrow evidence and things with none. Omega-3's systematic review of post-exercise inflammation and muscle damage found mixed results: one interleukin improved, another inflammatory marker did not differ, and soreness results conflicted (PMID 38999792). Its authors note the trials did not measure omega-3 status, so the findings need caution. Two further systematic reviews cover safety generally (PMID 37567449) and bleeding risk specifically (PMID 38742535). Ginger's systematic review of 109 randomised trials found consistent support for nausea and vomiting in pregnancy, inflammation, metabolic syndrome and digestion, and found the other claimed effects controversial (PMID 31935866). Fewer than two in five of those trials met its own bar for high-quality evidence. A separate meta-analysis covers period pain (PMID 38770631). Boswellia's systematic review and meta-analysis in osteoarthritis, seven trials, reported reduced pain and stiffness and improved joint function (PMID 32680575). A broader review of supplements for osteoarthritis found moderate short-term effects on pain and function on very low quality evidence, and no clinically important effects at medium or long term (PMID 29018060). It found glucosamine and chondroitin either ineffective or trivially effective. For diet, a systematic review and meta-analysis found anti-inflammatory diets gave significantly less pain in rheumatoid arthritis than ordinary diets (PMID 34959772). It rated every included study at high risk of bias and the evidence as very low. For exercise, a systematic review and meta-analysis included inflammatory markers among its outcomes (PMID 38887616).

1. **Work out which inflammation you mean.** A blood marker, a diagnosed condition, and post-training soreness are three different problems with three different answers. 2. **If it is a diagnosed autoimmune condition, it is managed with a clinician**, and the supplement evidence here is about symptoms alongside treatment, not instead of it. 3. **If it is a marker on a blood test, ask what the number is being used to predict** before trying to move it (PMID 38715129, 38353970). 4. **Exercise and diet have the broadest supporting evidence** and are the interventions the reviews above are built on (PMID 38887616, 34959772). 5. **If you take curcumin, know which formulation you have.** Absorption differs enormously between products and the trials are not interchangeable (PMID 17999464, 36720711).

Where the research supports a timeframe, the curcumin trials pooled in the dose-response meta-analysis generally ran over **weeks to months**. The outcomes were blood markers measured at the end of that period (PMID 36804260). The post-exercise omega-3 review measures effects around individual training sessions (PMID 38999792). No duration is offered for the marker studies, because they are cohort studies following people for years and describe prediction rather than an intervention.

- **Moving a marker is not the same as changing an outcome.** Every supplement result in this guide is a marker result. None of them demonstrates a reduction in disease. - **Curcumin trials are not comparable to each other or to your product** (PMID 17999464, 9619120, 36720711). Formulation changes how much reaches you, and a trial using an enhanced-absorption preparation does not describe a plain turmeric capsule. - **The GRADE assessment is the point of citing that review** (PMID 36804260). Selecting the favourable individual trials from underneath it is the standard way this evidence gets misrepresented. - **Post-exercise inflammation is a different thing from chronic inflammation** (PMID 38999792), and blunting it is not obviously desirable, because the inflammatory response after training is part of how adaptation happens. - **The osteoarthritis evidence is about joint symptoms, not about systemic inflammation** (PMID 32680575, 29018060). It is included here because boswellia is sold for inflammation, and the trials measured knees. - **Nothing here was tested in people already taking an immunosuppressant or a biologic**, which is the population most likely to be searching for it.

- **Turmeric and curcumin have a documented liver-injury signal.** A case series reported turmeric-associated liver injury (PMID 31283536), and a review sets out the wider problem of identifying herbal and supplement-induced liver injury (PMID 39136211). Anyone taking it daily, taking an enhanced-absorption product, or taking any other medicine processed by the liver should raise it with **a pharmacist or clinician**. - **Omega-3 and bleeding risk deserve a real answer rather than a rumour.** A systematic review and meta-analysis examined bleeding risk directly (PMID 38742535) alongside a broader safety review (PMID 37567449). If you take an anticoagulant or antiplatelet medicine, or have surgery coming up, raise it with **your prescriber or surgeon** rather than deciding from a forum. - **If you have a diagnosed inflammatory or autoimmune condition, do not substitute any of this for your treatment.** Raise additions with **the clinician who manages that condition**, because some of these compounds are being taken for the same effect the treatment is producing. - **An enhanced-absorption formulation is a different exposure from the plain spice** (PMID 9619120, 36720711). If you switch products, treat it as a change worth mentioning to **a clinician**, not as the same thing in a new bottle. - **Persistent unexplained inflammation markers, fevers, joint swelling, or weight loss belong with a doctor**, not with a supplement. They can indicate a condition that has a treatment.

Resolving to an entity and being interaction-checkable are different things. The interaction catalogue keys on a collapsed name string rather than an entity id. Resolves **and** has a catalogue key, so it can be interaction-checked: - `avelor:sup:ginger` - `avelor:sup:omega-3`, `avelor:sup:omega-3-fish-oil` Resolves but has **no catalogue key**, so it displays as recognised and is checked against nothing: - `avelor:sup:boswellia` - `avelor:sup:bromelain` - `avelor:sup:omega-3-fatty-acids` **Curcumin and turmeric have no supplement entity of any type.** Neither does quercetin, resveratrol, or piperine. That is the most consequential absence found in any guide so far, and not because curcumin is popular, though it is. It is because curcumin is the one compound in this guide with a documented liver-injury signal, and piperine is the thing that raises how much of it reaches you. So the product cannot resolve the compound whose safety question is real, cannot resolve the co-ingredient that makes that question larger, and cannot surface either when a user saves a stack. Every other absence recorded across these guides costs a check that would probably have returned nothing. This one costs the check most worth running.

| PMID | Title | | --- | --- | | 38715129 | "Joint association of TyG index and high sensitivity C-reactive protein with cardiovascular disease: a national cohort study" | | 38353970 | "Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations" | | 36804260 | "Antioxidant and anti-inflammatory effects of curcumin/turmeric supplementation in adults: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials" | | 37325651 | "Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis" | | 17999464 | "Bioavailability of curcumin: problems and promises" | | 9619120 | "Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers" | | 36720711 | "Curcumin-piperine co-supplementation and human health: A comprehensive review of preclinical and clinical studies" | | 38999792 | "Omega-3 Fatty Acid Supplementation on Post-Exercise Inflammation, Muscle Damage, Oxidative Response, and Sports Performance in Physically Healthy Adults-A Systematic Review of Randomized Controlled Trials" | | 37567449 | "Safety of Supplementation of Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" | | 38742535 | "Bleeding Risk in Patients Receiving Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Clinical Trials" | | 31935866 | "Ginger on Human Health: A Comprehensive Systematic Review of 109 Randomized Controlled Trials" | | 38770631 | "Ginger for Pain Management in Primary Dysmenorrhea: A Systematic Review and Meta-Analysis" | | 32680575 | "Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis" | | 29018060 | "Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis" | | 34959772 | "Effect of Anti-Inflammatory Diets on Pain in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis" | | 38887616 | "Effects of combined aerobic and resistance training on glycemic control, blood pressure, inflammation, cardiorespiratory fitness and quality of life in patients with type 2 diabetes and overweight/obesity: a systematic review and meta-analysis" | | 31283536 | "Turmeric-Associated Liver Injury" | | 39136211 | "Challenges in herbal-induced liver injury identification and prevention" |